The Minister of Health has, in terms of section 22A(2) of the Medicines and Related Substances Act, 1965 (Act No. 101 of 1965), on the recommendation of the Medicines Control Council, made the Schedules in the Schedule

SCHEDULE

In these Schedules, “the Act” means the Medicines and Related Substances Act, 1965 (Act No. 101 of 1965)

SCHEDULE 0

(a) All substances referred to in this Schedule are excluded when specifically packed, labelled and used for -

(i) industrial purposes including the manufacture or compounding of consumer items or products which have no pharmacological action or medicinal purpose, which are intended to be ingested by man or animals as food, or applied to the body as a cosmetic, and which are approved for such use in terms of the Foodstuffs, Cosmetics and Disinfectants Act, 1972 (Act No. 54 of 1972) or registered in terms of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947 (Act No. 36 of 1947); and

(ii) analytical laboratory purposes.

(b) All substances referred to in this Schedule include the following:
(i) The salts and esters of such substances, where the existence of such salts and esters is possible; and

(ii) All preparations and mixtures of such substances where such preparations and mixtures are not expressly excluded.

This Schedule includes all substances subject to registration in terms of the Act and which are not listed in any of the other Schedules.
SCHEDULE 1

(a) All substances referred to in this Schedule are excluded when specifically packed, labeled and used for –
   (i) industrial purposes including the manufacture or compounding of consumer items or products which have no pharmacological action or medicinal purpose; and
   (ii) analytical laboratory purposes.

(b) All substances referred to in this Schedule include the following:
   (i) The salts and esters of such substances, where the existence of such salts and esters is possible; and
   (ii) all preparations and mixtures of such substances where such preparations and mixtures are not expressly excluded.

(c) In terms of section 22A(4)(a)(v) of the Act, a practitioner, nurse or a person registered under the Health Professions Act, 1974 (Act No. 56 of 1974) other than a medical practitioner or dentist, may prescribe and supply to patients under their care, the Schedule 1 substances and medicines provided for in the Annexures, only within their scope of practice and subject to the conditions determined by the Medicines Control Council. The conditions and the Annexures will be published in the Gazette.

Acetanilide and alkyl acetanilides.
Acetarsol, when intended for human vaginal use.
Acyclovir, when intended for application to the lips in the early treatment of recurrent herpes simplex virus infections. (S4)
Anethole trithione.
Anticoagulants, when intended for application to the skin. (S4)
Antimalarials; chloroquine in combination with proguanil when intended specifically for malaria prophylaxis. (S4)
Antimicrobial substances, namely bacitracin, gramicidin, polymyxin B and tyrothricin,
when intended for application to the skin, nares and external ear, as excluded from the conditions of Schedule 4. (S2, S4)

Antimony potassium tartrate and antimony sodium tartrate; substances, preparations and mixtures containing 1.0 percent or more thereof.

Arsenic; substances, preparations and mixtures containing the equivalent of less than 0.01 percent of arsenic trioxide. (S2)

Azelaic acid.

Belladonna alkaloids; when specifically intended for topical application (S2).

Benzethonium chloride, when intended for human vaginal use.

Benzydamine; preparations and mixtures containing -

(a) 3 per cent or less of benzydamine when intended for application to the skin;

(b) 0.15 per cent or less of benzydamine when intended for use as a mouth rinse or for topical application in the mouth and throat: Provided that the total daily dose does not exceed 36 mg of benzydamine. (S3)

Beta-aminopropybenzene and beta-aminoisopropybenzene as excluded from the conditions of Schedule 5. (S5)

Bifonazole, when intended for application to the skin.

Bioallethrin.

Bitolterol.

Bufexamac, when intended for application to the skin.

Bunamidine.

Calcium salts; preparations thereof, when intended for injection, except when registered in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947.

Chlohexidine, when intended for human vaginal use.

Chloroform, preparations and mixtures containing less than 20 percent of chloroform. (S5)

Clotrimazole, when intended for application to the skin and when intended for human vaginal use, specifically for the treatment of recurrent vaginal candidiasis. (S4)

Dialysate preparations.

Diclofenac, when intended for application to the skin. (S2, S3)

Diosmine.

Dithiazanine.
Econazole, when intended for application to the skin and when intended for human vaginal use, specifically for the treatment of recurrent vaginal candidiasis. (S4)

Enilconazole, when intended for application to the skin. (S4)

Ephedra alkaloids (natural or synthetic) except ephedrine preparations and mixtures intended for application to skin, eyes, ears and nares containing 1,0 per cent or less of ephedra alkaloids, and other preparations and mixtures containing not more than 30 milligrams of ephedrine or ephedra alkaloids per dose. (S2, S5)

Ephedrine contained in products registered in terms of the Act, preparations and mixtures intended for application to the skin, eyes, ears and nares containing 1,0 per cent or less of ephedrine, and other oral preparations and mixtures containing not more than 30 milligrams of ephedrine per dose. (S2, S5)

Escin (aescin); medicinal preparations and mixtures thereof intended for application to the skin and containing 1,0 per cent or less of escin. (S3)

Ether (diethyl ether); all substances, preparations and mixtures containing less than 20 per cent of ether. (S5)

Ethylphenylephrine.

Etofenamate, when intended for application to the skin.

Felbinac, when intended for application to the skin.

Fenbendazole, except when registered in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947.

Fenticonazole, when intended for application to the skin.

Flubendazole, except when intended and registered as an anthelmintic in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947.

Flufenamic acid, when intended for application to the skin. (S3)

Flurbiprofen, when intended for application to the skin, including by transdermal patch, provided that in the case of application by transdermal patch indications are for use by adults and children 12 years and older and the treatment period is limited to 4 weeks. (S2, S3, S4)

Fluorescein, when intended for ophthalmic use.

Fluorides; oral medicinal preparations and mixtures thereof containing 0,25 milligrams or more of fluorine as fluoride per recommended daily dose, unless listed in another Schedule. (S4)
Gamma benzene hexachloride human medicinal preparations and mixtures when intended for application to the skin.

Glycosaminoglycan polysulphate (previously mucopolysaccharide poly-sulphuric acid ester) when intended for application to the skin. (S4)

O- (β-hydroxyethyl)rutosides.

Ibuprofen, when contained in preparations intended for application to the skin (S2, S3)

Idoxuridine, when intended for application to the skin. (S4)

Indanazoline.

Indomethacin, when intended for application to the skin. (S2, S3)

Injections, unless listed in another Schedule, except when registered in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947.

Irrigation fluids.

Isoconazole, when intended for application to the skin and when intended for human vaginal use specifically for the treatment of recurrent vaginal candidiasis. (S4)

Ketoconazole, when intended for application to the skin, except preparations and mixtures containing not more than 1.0 percent of ketoconazole, when intended for the prevention and treatment of dandruff. (S0, S4)

Ketoprofen, when intended for application to the skin. (S2, S3)

Lactobacillus acidophilus and Lactobacillus bifidus, when intended for therapeutic purposes, except when registered in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947.

Local anaesthetics, except when intended for ophthalmic and for parenteral use. (S2, S4)

Lufenuron, except when intended and registered as a systemic preparation against fleas in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947.

Luxabendazole, except when intended and registered as an anthelmintic in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947.

Lysozyme, when intended for application to the skin. (S4)

Malathion, except when intended and registered as an ectoparasiticide in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947.
Manganese salts, preparations thereof for injection, when intended for veterinary use.

Mebendazole, except intended and registered as an anthelmintic in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947.

Methenamine (hexamine), except when intended for application to the skin and except when intended and registered as an urinary tract antiseptic in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947.

Methionine, when intended for medicinal purposes.

Miconazole when intended for application to the skin and when intended for human vaginal use, specifically for the treatment of recurrent vaginal candidiasis. (S2, S4)

Microfibrillar collagen hydrochloride.

Morantel citrate, except when intended and registered as an anthelmintic in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947.

N-acetyl-aspartyl-glutamic acid.

Naphazoline, when intended for nasal use.

Naproxen, when intended for application to the skin (S2, S3)

Nicotine; when used as nicotine transdermal patches for continuous application to the skin in strengths up to and including 15mg/16 hours when these medicines are used for the relief of nicotine withdrawal symptoms as an aid to smoking cessation only. (S2)

except-

nicotine gum containing 4mg or less nicotine per piece where the pack size does not exceed 30 pieces per pack when these medicines are used for the relief of nicotine withdrawal symptoms as an aid to smoking cessation only (S0).

Nitrofurantoin, when intended for application to the skin. (S4)

Nitrofurazone, when intended for application to the skin. (S4)

Nystatin, when intended for application to the skin and when intended for human vaginal use, specifically for the treatment of recurrent vaginal candidiasis. (S4)

Omidazole, when intended for application to the skin. (S4)

Orthodichlorobenzene, when intended for topical human medicinal use.

Oxibendazole, except when intended and registered as an anthelmintic in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947.
Oxymetazoline, when intended for nasal use.

Paracetamol -

(1) substances, preparations and mixtures, except -

(a) in tablets or capsules each containing 500 milligrams or less of paracetamol, when-

(i) packed in a primary pack containing not more than an aggregate of 12.5 grams of paracetamol in such tablets or capsules;
(ii) packed in blister strip packaging or in containers with child-resistant closures;
(iii) the primary pack is labeled with the following boxed warning, placed prominently on at least the main panel of the immediate container label and outer label (carton):

CONTAINS PARACETAMOL- READ THE PACKAGE INSERT;

(b) in individually wrapped powders or in sachets containing 1000 milligrams or less of paracetamol, when-

(i) packed in a primary pack containing not more than an aggregate of 12.5 grams of paracetamol in such powders or sachets;
(ii) the primary pack is labelled with the following boxed warning, placed prominently on at least the main panel of the immediate container label and outer label (carton):

CONTAINS PARACETAMOL- READ THE PACKAGE INSERT;

(c) in liquid or syrup dosage form containing 120 milligrams or less of paracetamol per 5 millilitres or in pediatric dosage form (drops) containing 120 milligrams or less of paracetamol per 1.2 millilitres, when -

(i) packed in a primary pack containing not more than 100 millilitres in the case of the liquid or syrup dosage form containing 120 milligrams or less of paracetamol per 5 millilitres;
(ii) packed in a primary pack containing not more than 20 millilitres in the case of the paediatric dosage form (drops) containing 120 milligrams or less of paracetamol per 1.2 millilitres;
(iii) the primary pack is labelled with the following boxed warning, placed prominently on at least the main panel of the immediate container label and outer label (carton):

CONTAINS PARACETAMOL- READ THE PACKAGE INSERT.

(2) when contained in rectal suppositories. (S2)

Paradichlorobenzene, when intended for topical human medicinal use.
Penciclovir, when intended for application to the lips in the early treatment of recurrent Herpes simplex virus infections. (S4)
Pentosan polysulfate sodium, except when intended for the treatment of interstitial cystitis. (S3)
Phenylephrine, except ophthalmic preparations containing 0.2 per cent or less of phenylephrine.
Phospholipids, when applied for therapeutic purposes.
Procaine hydrochloride, when intended for oral administration.
Proguanil when used in combination with chloroquine when intended specifically for malaria prophylaxis. (S4)
Propentofylline, when intended for veterinary use. (S4)
Propylhexedrine, when used as a vasoconstrictor and decongestant in nose preparations and inhalants (S4)
Proteolytic (fibrinolytic) enzymes for oral use and when intended for application to the skin, unless listed in another Schedule, and except when intended for soft contact lens cleaners and except when intended for injection (S0, S4)
Pyrantel pamoate, including veterinary use, except when intended and registered as an anthelmintic in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947.
Pyridoxilate.
Sertaconazole, when intended for application to the skin. (S4)
Sodium fluoride; preparations and mixtures thereof containing 40 milligrams or more per daily dose. (S4)
Terbinafine, when intended for application to the skin. (S4)
Tetrahydrozoline, when intended for nasal use.
Thiabendazole, when intended for application to the skin. (S4)
Thiram, except when intended and registered as a fungicide in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947.

Ticlatone, when intended for application to the skin.

Tioconazole, when intended for application to the skin and when intended for human vaginal use, specifically for the treatment of recurrent vaginal candidiasis. (S4)

Tolmetin, when intended for application to the skin. (S3)

L-tryptophan when intended for medicinal use as supplementation for nutritional purposes. (S5)

Xylometazoline, when intended for nasal use.

Zinc salts, preparations thereof for injection, when intended for veterinary use. (S3)

END SCHEDULE 1
Schedule 2

(a) All substances referred to in this Schedule are excluded when specifically packed, labelled and used for -

(i) Industrial purposes including the manufacture or compounding of consumer items or products, which have no pharmacological action or medicinal purpose; and

(ii) Analytical laboratory purposes.

(b) All substances referred to in this Schedule include the following:

(i) The salts and esters of such substances, where the existence of such salts and esters is possible; and

(ii) All preparations and mixtures of such substances where such preparations and mixtures are not expressly excluded.

(c) In terms of Section 22A(5)(f) of the Act, a practitioner, nurse or a person registered under the Health Professions Act, 1974, other than a medical practitioner or dentist, may prescribe and supply to patients under their care, the Schedule 2 substances and medicines provided for in the Annexures, only within their scope of practice and subject to the conditions determined by the Medicines Control Council. The conditions and the Annexures will be published in the Government Gazette.

Acetylcysteine.

Acetyldihydrocodeine; preparations and mixtures when compounded with one or more therapeutically active substances and containing 20 milligrams or less of acetyldihydrocodeine (calculated as base) per dosage unit and liquid oral preparations and mixtures containing 20 milligrams or less of acetyldihydrocodeine (calculated as base) per 5 millilitre dosage unit. (S6)

Aconite alkaloids; substances, preparations and mixtures containing 0,02 percent or more thereof.

Acrivastine.
Adrenaline (epinephrine), except ophthalmic preparations when intended for glaucoma and except preparations for injection. (S3, S4)

Alkaloids and glycosides; all poisonous alkaloids and glycosides, and the salts of such poisonous alkaloids and glycosides not specifically named in any other Schedule.

Alverin.

Aminopentamide

Amorolfine.

Amyl nitrite

Antihistamines, irrespective of indication or dosage form, except-

(a) astemizole and terfenadine; (S4)

(b) when listed separately in these Schedules; (S2,S5) and

(c) except when registered in terms of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947.

Antimicrobial substances, namely griseofulvin, mupirocin, natamycin, when intended for application to the skin, nares and external ear, as well as nystatin preparations intended for application to the oral cavity, nares and external ear and excluding nystatin when intended for application to the skin and for human vaginal use, specifically for the treatment of recurrent vaginal candidiasis, as excluded from the conditions of Schedule 4. (S1, S4)

Apomorphine; preparations and mixtures thereof, except when indicated for the treatment of erectile dysfunction. (S4)

Aptocaine.

Arecoline.

Arsenic; substances, preparations and mixtures containing the equivalent of 0.01 percent or more of arsenic trioxide. (S1)

Atropine; substances, preparations and mixtures thereof, except ophthalmic preparations. (S3)

Azelasin.

Bambuterol.

Beclomethasone dipropionate, when intended for nasal administration (other than by aerosol), in the treatment of the symptoms of seasonal allergic rhinitis (hay fever) in adults and children over 12, subject to-

(a) a maximum dose of 100 micrograms per nostril;

(b) a maximum daily dose of 200 micrograms per nostril;
(c) a pack size limit of 200 doses. (S3, S4).
Belladonna alkaloids; substances, preparations and thereof, except when intended for
topical application (S1)
Benproperine.
Bevonium methylsulphate.
Biologicals, when intended for human medicinal use, including polyvalent snake
antivenom, and except other injectable preparations thereof (S4).
Bismuth, when intended for oral use.
Bromhexine.
Bromides; preparations and mixtures thereof containing less than 80 milligrams of
bromine as bromide per recommended daily dose. (S5)
Butinoline.
Calabar bean alkaloids; substances, preparations and mixtures thereof.
Camphorated Opium Tincture BP.
Camylofin.
Cantharidin
Canthaxanthin; when intended for medicinal purposes
Carbocisteine.
Carbuterol, except when contained in respirator solutions (S3) and except when
intended for injection. (S4)
Carisoprodol.
Cathine ((+)-norpseudoephedrine); preparations and mixtures containing 50 milligrams
or less of cathine per dosage unit. (S6)
Cetirizine.
Chlormezanone; mixtures thereof where the maximum recommended or prescribed
dose does not exceed 100 milligrams of chlormezanone. (S5)
Chlorodyne (Chloroform and Morphine Tincture BP 1980); or any preparation or mixture
thereof described as chlorodyne: preparations and mixtures containing 5.0
percent or less of chlorodyne in combination with other active medicinal
ingredients. (S6)
Chloroprenaline.
Cholestyramine.
Chlorzoxazone.
Clonidine when intended for treatment of migraine. (S3)
Cimetidine, when intended for the short-term symptomatic relief of heartburn, dyspepsia and hyperacidity, subject to-
(a) a maximum dose of 200 milligrams;
(b) a maximum daily dose (per 24 hours) of 800 milligrams;
(c) a maximum treatment period of 2 weeks. (S3)

Clidinium bromide.

Codeine (methylmorphine); preparations and mixtures when compounded with one or more therapeutically active substances and containing 20 milligrams or less of codeine (calculated as base) per dosage unit and liquid oral preparations and mixtures containing 20 milligrams or less of codeine (calculated as base) per 5 millilitre dosage unit. (S6)

Colchicine, in cases of emergency. (S3)

Contrast media

Cyclandelate.

Cyclopentolate, except ophthalmic preparations thereof. (S3)

Desloratidine.

Dextromethorphan.

Diclofenac, when intended for the emergency treatment of acute gout attacks, and when intended for the treatment of post traumatic conditions such as pain, swelling and inflammation, for maximum period of 5 days. (S1, S3)

Dicyclomine.

Difenoxin (or diphenoxyllic acid); mixtures containing, per dosage unit, 0.5 milligrams or less of difenoxin, calculated as the base, and a quantity of atropine sulphate equal to at least 5.0 per cent of such quantity of difenoxin, calculated as the base, as is present in the mixture. (S6)

Dihydrocodeine; preparations and mixtures when compounded with one or more therapeutically active substances and containing 20 milligrams or less of dihydrocodeine (calculated as base) per dosage unit and liquid oral preparations and mixtures containing 20 milligrams or less of dihydrocodeine (calculated as base) per 5 millilitre dosage unit. (S6)

Diphenoxylate; preparations containing not more than 2.5 milligrams of diphenoxylate, calculated as the base, and not less than 25 micrograms of atropine sulphate per dosage unit. (S6)

(D-norpseudoephedrine - see cathine)
Domperidone.
Emedastine.
Emepronium.
Ephedra alkaloids (natural or synthetic), other than ephedrine preparations and mixtures intended for application to the skin, eyes, ears and nares containing 1.0 percent or less of ephedra alkaloids, and other preparations and mixtures containing not more than 30 milligrams of ephedrine or ephedra alkaloids per dose. (S1, S5)
Ephedrine contained in products registered in terms of the Act, except preparations and mixtures intended for application to the skin, eyes, ears and nares containing 1.0 percent or less of ephedrine, and other oral preparations and mixtures containing not more than 30 milligrams of ephedrine per dose. (S1, S5)
Ergot alkaloids (natural or synthetic), when intended for the treatment of migraine. (S4)
Ethylmorphine; preparations and mixtures when compounded with one or more therapeutically active substances and containing 20 milligrams or less of ethylmorphine (calculated as base) per dosage unit and liquid oral preparations and mixtures containing 20 milligrams or less of ethylmorphine (calculated as base) per 5 millilitre dosage unit. (S6)
Etilefrine.
Exalamide.
Famotidine, when intended for the short-term symptomatic relief of heartburn caused by excess acid, subject to-
(a) a maximum dose of 10 milligrams;
(b) a maximum daily dose (per 24 hours) of 20 milligrams;
(c) a maximum treatment period of 2 weeks. (S4)
Fedrilate
Fenoprofen, when intended for the emergency treatment of acute gout attacks and when intended for the treatment of post traumatic conditions such as pain, swelling and inflammation, for a maximum period of 5 days. (S3)
Fenoterol, except when contained in respirator solutions (S3) and except when intended for injection or for the prevention or delay of labour. (S4)
Flavoxate.
Flunisolide, when intended for nasal administration, other than by aerosol in a strength not exceeding 0.025 per cent (w/v), indicated for treatment of the symptoms of seasonal allergic rhinitis (hay fever) in adults and children over 12, subject to:
(a) a maximum dose of 50 micrograms per nostril and a maximum daily dose of 100 micrograms per nostril in the case of adults and children over the age of 16 years;
(b) a maximum dose of 25 micrograms per nostril and a maximum daily dose of 75 micrograms per nostril in the case of children 12 to 16 years of age; and
(c) a pack size containing not more than 240 doses. (S3, S4)

Flurbiprofen, when supplied by a pharmacist to a patient and intended for the treatment of post-traumatic conditions such as pain, swelling and inflammation, for a maximum period of 5 days. (S1, S3, S4)

Fluticasone propionate, when intended for nasal administration (other than by aerosol), in the short-term (less than 6 months) prophylaxis and treatment of symptoms of allergic rhinitis (hay fever) in adults and children over 12, subject to:
(a) a maximum daily dose of 100 micrograms per nostril;
(c) a pack size limit of 120 doses. (S3).

Formoterol.
Fusafungine.
Gadopentetic acid
Gelsemium alkaloids; substances, preparations and mixtures thereof.
Glycopyrronium.
Halogenated hydroxyquinolines, when intended for application to the skin. (S4)
Hexametazine.
Hexoprenaline, except when contained in respirator solutions (S3) and except when intended for injection or for the prevention or delay of labour. (S4)
Homatropine; preparations and mixtures thereof, except ophthalmic preparations. (S3)
Hormones (Natural or synthetic, including recombinant forms), with either hormonal or anti-hormonal action, when intended for human vaginal use and oral contraceptives containing only progestogen and hormones when specifically intended for emergency postcoital contraception. (S3, S4, S5)
Hydrocortisone and hydrocortisone acetate, when used in a maximum concentration of 1.0 percent in preparations intended for application to the skin and hydrocortisone in
a maximum concentration of 1,0 percent used in combination with miconazole for topical application in the treatment of athlete’s foot. (S4)

Hydroquinone; preparations and mixtures containing 2 percent or less thereof, when intended for application to the skin. (S3)

Hyoscine; substances, preparations and mixtures thereof, including transdermal preparations when intended for the prevention of the symptoms of motion sickness.

Ibuprofen when used in oral medicinal preparations –
  a. where the recommended daily dose for adults does not exceed 1,2 grams and that for children up to and including the age of 12 years does not exceed 20 milligrams per kilogram of body weight;
  b. the emergency treatment of acute gout attacks;
  c. when intended for the treatment of post traumatic conditions such as pain, swelling and inflammation, for a maximum period of 5 days;
     except when intended for treatment of inflammatory joint disease (S3)

Indomethacin, when intended for the emergency treatment of acute gout attacks. (S1, S3)

Lopromide

Ipratropium bromide.

Isoaminile.

Isoprenaline (isoproterenol), except when contained in respirator solutions (S3) and except when intended for injection. (S4)

Isopropamide.

Ketoprofen,
  a) when intended for the short term management of headache, toothache, muscular ache, backache, minor pain associated with arthritis, pain associated with menstrual cramps (dysmenorrheoa), minor aches and pains associated with the common cold and fever, at a maximum dose of 75 milligrams of ketoprofen in 24 hours;
  b) when supplied by a pharmacist to a patient and intended for the emergency treatment of acute gout attacks or for the treatment of post traumatic conditions such as pain, swelling and inflammation, at a maximum dose of 100mg of ketoprofen per day, for a maximum period of 5 days. (S1, S3)
Lansoprazole, when intended for the temporary short-term relief of heartburn and hyperacidity, subject to—
   a) a maximum daily dose of 15mg
   b) a maximum treatment period of 14 days. (S4)

Levocetirizine.

Lithium salts, when intended for application to the skin. (S5)

Lobelia alkaloids; substances, preparations and mixtures thereof.

Lodoxamide.

Loperamide

Loratadine.

Mebeverine.

Mefenamic acid, when intended for the treatment of post traumatic conditions such as pain, swelling and inflammation, for a maximum period of 5 days; and preparations containing mefenamic acid as the only therapeutic active substance, when intended for the treatment of primary dysmenorrhoea where the maximum daily dose is 500 milligrams 3 times a day and the maximum treatment period is 3 days. (S3)

Mepenzolate bromide.

Mephenesin.

Mercuric ammonium chloride.

Mercuric chloride.

Mercuric iodide.

Mercuric oxides; substances, preparations and mixtures thereof, except those containing less than 3 per cent of mercury.

Mercury organic compounds; substances, preparations and mixtures in the form of aerosols, intended for application to the skin and mucous membranes and substances, preparations and mixtures containing the equivalent of 0.6 per cent or more of elemental mercury, intended for application to the skin and mucous membranes, except phenylmercuric nitrate when registered in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947 (Act No. 36 of 1947).

Mesna, except preparations intended for injection. (S4)

Metaproterenol (orciprenaline) except when contained in respirator solutions (S3) and except when intended for injection or for the prevention or delay of labour (S4).
Methixene
Methocarbamol, when intended for medicinal purposes
Methoxyphenamine
Miconazole, when intended for human use in preparations containing 2 percent or less of miconazole, for the topical treatment of fungal infections of the mouth (oral candidiasis). (S1, S4)
Minoxidil, when intended for application to the scalp. (S4)
Morphine; mixtures containing 0.2 percent or less of morphine, calculated as anhydrous morphine. (S6)
Nabumetone, when intended for the treatment of post-traumatic conditions such as pain, swelling and inflammation, for a maximum period of 5 days. (S3)
Naproxen, a) as the sodium salt, when intended for the short term management of headache, toothache, muscular ache, backache, minor pain associated with arthritis, pain associated with menstrual cramps (dysmenorrhea), minor aches and pains associated with the common cold and fever, at a maximum dose of 600 milligrams naproxen (660 milligrams naproxen sodium) in 24 hours;
b) and when supplied by a pharmacist to a patient and intended for the emergency treatment of acute gout attacks or for the treatment of post traumatic conditions such as pain, swelling and inflammation, for a maximum period of 5 days. (S1, S3)
Nedocromil
Nicergoline
Nicotine when intended for human medicinal use, except-
(a) nicotine gum containing 4mg or less nicotine per piece where the pack size does not exceed 30 pieces per pack when these medicines are used for the relief of nicotine withdrawal symptoms as an aid to smoking cessation only (S6).
(b) nicotine transdermal patches for continuous application to the skin in strengths up to and including 15mg/16 hours when these medicines are used for the relief of nicotine withdrawal symptoms as an aid to smoking cessation only. (S1)
Nizatidine, when administered orally for short-term symptomatic relief of heartburn and hyperacidity, subject to-
(a) a maximum dose of 150 milligrams;
(b) a daily dose of 300 milligrams
(c) a maximum treatment period of two weeks. (S4)

Norcodeine; preparations and mixtures when compounded with one or more therapeutically active substances and containing 20 milligrams or less of norcodeine (calculated as base) per dosage unit and liquid oral preparations and mixtures containing 20 milligrams or less of norcodeine (calculated as base) per 5 millilitre dosage unit. (S6)

Noscapine
Nux vomica; substances, preparations and mixtures thereof, except when registered in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947.

Octatropine methylbromide.

Oleoresin of aspidium (Filia Mas).

Olopatadine.

Opium; mixtures containing not more than 0.2 percent of morphine, calculated as anhydrous morphine. (S6)

Orphenadrine.

Otilonium bromide.

Oxybuprocaine, when contained in eye drops intended for emergency treatment of arc eyes. (S4)

Oxyphencyclimine.

Oxyphenonium.

Papaverine; substances, preparations and mixtures thereof.

Paracetamol, when contained in rectal suppositories. (S0, S1)

Pentoxyfylline

Phenazone (antipyrone)

Phenazopyridine

Phenylpropanolamine, preparations and mixtures where the recommended daily dose for adults does not exceed 100 milligrams and for children 6 to 12 years, does not exceed 50 milligrams, when intended for the symptomatic relief of nasal and sinus congestion.
Pholcodine; preparations and mixtures when compounded with one or more therapeutically active substances and containing 20 milligrams or less of pholcodeine (calculated as base) per dosage unit and liquid oral preparations and mixtures containing 20 milligrams or less of pholcodeine (calculated as base) per 5 millilitre dosage unit. (S6)

Pholedrine
Pinaverium
Piperzolate
Pipoxolan
Pirbuterol, except when contained in respirator solutions. (S3)

Piroxicam, when intended for the emergency treatment of acute gout attacks and when intended for the treatment of post traumatic conditions such as pain, swelling and inflammation, for a maximum period of 5 days. (S3)

Pizotifen; preparations and mixtures, when intended for prophylaxis of migraine (S5)

Podophyllum resin; preparations and mixtures containing 20 percent or less thereof. (S4)

Poldine methylsulphate.

Polyvalent snake antivenom.

Potassium chloride, where the recommended dose is more than 20 millimol of potassium (1500 milligrams of potassium chloride) per 24 hours or when intended for intravenous infusion or for injection, but except when contained in oral rehydration preparations. (S0)

Prifinium bromide.

Procaterol, except when contained in respirator solutions. (S3)

Procyclidine

Proglumide

Promethazine; preparations and mixtures when intended for use as an antihistamine, for application to the skin and when intended specifically for the treatment of travel sickness. (S5)

Propantheline bromide.

Propyphenazone

Proxymetacaine, when contained in eye drops intended for emergency treatment of arc eyes. (S4)

Quinine; preparations and mixtures containing more than 1,0 percent thereof.
Ranitidine, when administered orally for short-term symptomatic relief of heartburn and hyperacidity, subject to-
(a) a maximum dose of 75 milligrams;
(b) a daily dose of 300 milligrams
(c) a maximum treatment period of two weeks. (S3)
Reproterol, except when contained in respirator solutions. (S3)
Rimiterol, except when contained in respirator solutions (S3) and except when intended for injection. (S4)
Sabadilla alkaloids; substances, preparations and mixtures containing 1,0 per cent or more thereof.
Salbutamol, except when contained in respirator solutions (S3) and except when intended for injection. (S4)
Salmefamol, except when contained in respirator solutions (S3) and except when intended for injection. (S4)
Salmeterol.
Siccanin, when intended for application to the skin.
Silver sulphadiazine, when intended for application to the skin in the short-term treatment of minor burns, provided that the pack size is limited to a maximum of 50 grams. (S4)
Sodium cromoglycate, except when intended for veterinary use. (S4)
Strychnine; preparations and mixtures containing 0,2 percent or less thereof, except the substance. (S4)
Sulphonamides, when intended for application to the eyes, nares and vagina, (S4), except when registered in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947 (Act No. 36 of 1947).
Terbutaline, except when contained in respirator solutions. (S3)
Tetracaine, when contained in eye drops intended for emergency treatment of arc eyes. (S4)
Theophylline and its derivatives, unless listed in another Schedule, except preparations for injection. (S4)
Tiaprofenic acid, when intended for the treatment of post-traumatic conditions such as pain, swelling and inflammation, for a maximum period of 5 days. (S3)
Timepidium.
Tiotropium.
Triamcinolone, when intended for application to oral lesions. (S4)

Trimebutine

Trospium.

Tuberculin, when intended for human use (S4)

Tulobuterol, except when contained in respirator solutions. (S3)

Vaccines, when intended for human use

- END SCHEDULE 2 -
Schedule 3

(a) All substances referred to in this Schedule are excluded when specifically packed, labelled and used for -
(i) industrial purposes including the manufacture or compounding of consumer items or products, which have no pharmacological action or medicinal purpose; and
(ii) analytical laboratory purposes.

(b) All substances referred to in this Schedule include the following:
(i) The salts and esters of such substances, where the existence of such salts and esters is possible; and
(ii) all preparations and mixtures of such substances where such preparations and mixtures are not expressly excluded.

(c) In terms of Section 22A(5)(f) of the Act, a practitioner, nurse or a person registered under the Health Professions Act, 1974, other than a medical practitioner or dentist, may prescribe and supply to patients under their care, the Schedule 3 substances and medicines provided for in the Annexures, only within their scope of practice and subject to the conditions determined by the Medicines Control Council. The conditions and the Annexures will be published in the Gazette.

Acamprosate.
Acebutolol.
Aceclofenac.
Acetazolamide.
Acetohexamide.

Acetylcholine, when intended for ophthalmic use.
Acipimox.
Adapalene.

Adrenaline (epinephrine); ophthalmic preparations thereof, when intended for glaucoma.
(S2, S4)
Alclofenac.
Alendronic acid.
Allopurinol.
Alprenolol.
Amiloride.
Amodipine.
Ancrod.
Anthiolimine, when intended for injection.
Arsanilic acid.
Atenolol.
Atropine; ophthalmic preparations thereof. (S2)
Azapropazone.
Balsalazide.
Bamidipine.
Beclamide.
Benazepril.
Bendazac.
Benfluorex.
Benoxaprofen.
Benzbromarone.
Benzydamine, except preparations and mixtures containing -
(a) 3 per cent or less of benzydamine when intended for application to the skin;
(b) 0.15 per cent or less of benzydamine when intended for use as a mouthrinse or for topical application in the mouth and throat: Provided that the total dose does not exceed 36 mg of benzydamine per day. (S1)
Bepridil.
Beta-benzalbutyramide.
Beta-galactosidase, when intended for therapeutic purposes.
Betahistine.
Betaxolol.
Bethanidine.
Bevantolol.
Bezafibrate.
Bisoprolol.
Bopindolol.
Brimonidine.
Brinzolamide.
Buflomedil.
Buformin.
Bumetanide.
Cadralazine.
Calcipotriol.
Calcium carbimide.
Calcium disodium edetate, when intended for injection.
Calcium dobesilate.
Candesartan.
Captopril.
Carazolol.
Carbachol; ophthalmic preparations thereof when intended for glaucoma. (S4)
Carbamazepine.
Carbenoxolone, except when intended for application to the oral mucosa.
Carbuterol, when contained in respirator solutions. (S2, S4)
Carprofen.
Carteolol.
Carvedilol.
Celecoxib.
Celiprolol.
Chenodeoxycholic acid.
Chlorazanil.
Chlorexolone.
Chlorothiazide and other derivatives of benzo-1,2,4-thiadiazine-7-sulphonamide-1,1-dioxide, whether hydrogenated or not, including hydrochlorothiazide, bendrofluazide, benzthiazide, cyclopenthiazide, hydroflumethiazide, metchlorothiazide and polythiazide.
Chlorpropamide.
Chlorthalidone.
Chromonar.
Cilazapril.
Cimetidine, except when intended for the short-term symptomatic relief of heartburn, dyspepsia and hyperacidity, where the maximum dose is 200 milligrams, the maximum daily dose (per 24 hours) is 800 milligrams and the maximum treatment period is 2 weeks. (S2)

Clofibrate.

Clonidine, except when intended for the treatment of migraine. (S2)

Clopidogrel.

Colchicine, except in cases of emergency. (S2)

Colestipol.

Copper salts, when intended for injection.

Corticosteroids (natural or synthetic), when contained in preparations intended for inhalation, except-

(a) beclomethasone dipropionate, when intended for nasal administration, other than by aerosol, indicated for the treatment of the symptoms of seasonal allergic rhinitis (hay fever) in adults and children over 12, where the maximum dose per nostril is 100 micrograms, the maximum daily dose per nostril is 200 micrograms and the pack size is limited to 200 doses; and

(b) flunisolide, when intended for nasal administration, other than by aerosol, in a strength not exceeding 0.025 per cent (w/v), indicated for treatment of the symptoms of seasonal allergic rhinitis (hay fever) in adults and children over 12, where in the case of adults and children over the age of 16 years, the maximum dose per nostril is 50 micrograms and the maximum daily dose per nostril is 100 micrograms and in the case of children 12 to 16 years, the maximum dose per nostril is 25 micrograms and the maximum daily dose per nostril is 75 micrograms and the pack size is limited to 240 doses and

(c) fluticasone propionate, when intended for nasal administration, other than by aerosol, in the short-term (less than 6 months) prophylaxis and treatment of symptoms of allergic rhinitis (hay fever) in adults and children over 12, where the maximum daily dose per nostril is 100 micrograms and the pack size is limited to 120 doses. (S2, S4)

Cyclandelate

Cyclopentolate; ophthalmic preparations thereof. (S2)

Debrisoquine.

Delapril.
Dichlorphenamide.

Diclofenac, except when intended for application to the skin, (S1) and except when intended for the emergency treatment of acute gout attacks and except when intended for the treatment of post traumatic conditions such as pain, swelling and inflammation, for a maximum period of 5 days. (S2)

Diflunisal.

diflalone.

Digitalis; its glycosides and other active principles thereof, unless diluted below one unit (BP) in each 2.0 grams.

Dihydroergocristine.

Dilevalol.

Diltiazem.

Dimercaprol, when intended for injection.

Dipivefrin.

Dipyriramol.

Dipyrrocetyl.

Disulfiram.

Dithranol.

Dornase alfa (rh DNase).

Dorzolamide.

Doxazosin.

Eltenac.

Enalapril.

Endralazine.

Eprosartan.

Escin (aescin), except preparations and mixtures thereof intended for application to the skin and containing 1.0 percent or less of escin. (S1)

Esculin, when intended for oral use.

Esmolol.

Ethacrynic acid.

Ethambutol.

Ethionamide, when intended for oral use.

Ethosuximide.

Etisazol.
Etodolac.
Etodolic acid.
Felbamate.
Felodipine.
Fenbufen.
Fenclofenac.
Fendiline.
Fenofibrate.
Fenoprofen, except when intended for the emergency treatment of acute gout attacks and when intended for the treatment of post traumatic conditions such as pain, swelling and inflammation, for a maximum period of 5 days. (S2)
Fenoterol, when contained in respirator solutions. (S2, S4)
Fentiazac.
Floctafenine.
Flufenamic acid, except preparations and mixtures intended for application to the skin. (S1)
Flunixin.
Flurbiprofen, except -
(a) when intended for ophthalmic use; (S4)
(b) when intended for application to the skin, including application by transdermal patch, the indications are for use by adults and children 12 years and older and the treatment period is limited to 4 weeks; (S1)
(c) when supplied by a pharmacist to a patient and intended for the treatment of post-traumatic conditions such as pain, swelling and inflammation, for a maximum period of 5 days. (S2)
Fosinopril.
Furosemide.
Gabapentin.
Gemfibrozil.
Glafenine.
Glibenclamide.
Glibomuride.
Gliclazide.
Glimepiride.
Glimidine.
Glipizide.
Gliquidone.
Glucosamine, substances, preparations and mixtures when intended for the treatment of primary and secondary osteoarthritis, osteochondrosis and spondylosis.
Guanabenz.
Guanethidine.
Guanfacine.
Guanoxan.
Hexoprenaline, when contained in respirator solutions. (S2, S4)
Homatropine; ophthalmic preparations thereof. (S2)
Hormones (natural or synthetic, including recombinant forms), when intended for oral contraception, except oral contraceptives containing only progestogen and except hormones when specifically intended for emergency postcoital contraception. (S2, S4, S5)
Hydralazine.
Hydroquinone; preparations and mixtures thereof containing more than 2.0 percent hydroquinone. (S2)
Ibuprofen, when specifically intended for the treatment of inflammatory joint diseases. (S1, S2)
Indapamide.
Indomethacin, except when intended for application to the skin, and except when intended for the emergency treatment of acute gout attacks. (S1, S2)
Indoprofen.
Indoramin.
Insulin
Irbesartan.
Iron salts, when intended for injection, except when registered in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947.
Isoniazid and its derivatives, unless listed in another Schedule.
Isoprenaline (isoproterenol), when contained in respirator solutions. (S2, S4)
Isosorbide.
Isoxicam.
Isradipine.

Ivermectin, except when intended and registered as an anthelmintic and/or ectoparasiticide in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947.

Ketanserin.

Ketoprofen, except:

(a) when intended for application to the skin; (S1)
(b) when intended for the short term management of headache, toothache, muscular ache, backache, minor pain associated with arthritis, pain associated with menstrual cramps (dysmenorrhoa), minor aches and pains associated with the common cold and fever, at a maximum dose of 75 milligrams of ketoprofen in 24 hours; (S2)
(c) when supplied by a pharmacist to a patient and intended for the emergency treatment of acute gout attacks or for the treatment of post-traumatic conditions such as pain, swelling and inflammation, at a maximum dose of 75mg of ketoprofen per day, for a maximum period of 5 days. (S2)

Ketorolac trometamol, when intended for ophthalmic use. (S4)

Labetalol.

Lacidipine.

Lamotrigine.

Lercanidipine.

Levetiracetam.

Levobunolol.

Levocemindan.

Lidoflazine.

Lisinopril.

Lonazolac.

Lomoxicam.

Losartan.

Meclofenamic acid.

Mefenamic acid, except when intended for the treatment of post-traumatic conditions such as pain, swelling and inflammation, for a maximum period of 5 days; and except preparations containing mefenamic acid as the only therapeutic active substance, when intended for the treatment of primary dysmenorrhoea where the
Maximum daily dose is 500 milligrams of mefanamic acid 3 times a day and the maximum treatment period is 3 days. (S2)

Meloxicam.
Mepindolol.
Mesalazine (5-aminosalicylic acid).
Mesulphene.
Metaproverenol (orciprenaline), when contained in respirator solutions. (S2, S4)
Metformin.
Methazolamide.
Methimazole.
Methsuximide.
Methyldopa.
Metipranolol.
Metolazone.
Metoprolol.
Mibefradil.
Moexipril.
Montelukast.
Moxonidine.
Nabumetone, except when intended for the treatment of post-traumatic conditions such as pain, swelling and inflammation, for a maximum period of 5 days. (S2)

Nadolol.
Naftidrofuryl.
Naproxen, except -
(a) when intended for application to the skin; (S1)
(b) the sodium salt, when intended for the short term management of headache, toothache, muscular ache, backache, minor pain associated with arthritis, pain associated with menstrual cramps (dysmenorrhea), minor aches and pains associated with the common cold and fever, at a maximum dose of 600 milligrams naproxen (660 milligrams naproxen sodium) in 24 hours; (S2)
(c) when supplied by a pharmacist to a patient and intended for the emergency treatment of acute gout attacks or for the treatment of post traumatic conditions such as pain, swelling and inflammation, for a maximum period of 5 days. (S2)

Nateglinide.
Nebivolol.
Nicardipine.
Nifedipine.
Niflumic acid.
Nimesulide.
Nimodipine.
Nisoldipine.
Nitrendipine.
Nitroglycerine, when intended for medicinal use.
Olsalazine.
Orlistat.
Oxaprozin.
Oxcarbazepine.
Oxitracetam.
Oxvinca.
Oxyprenolol.
Oxybutynin.
Parecoxib
Para-aminosalicylic acid and its esters.
Penbutolol.
Penicillinase, when intended for injection.
Pentaerythritol tetranitrate.
Pentolinium.
Pentosan polysulfate sodium, when intended for the treatment of interstitial cystitis. (S1)
Perindopril.
Phenformin.
Phenobarbital, preparations and mixtures containing not more than 90 milligrams of phenobarbital per minimum recommended or prescribed dose when intended for continued use in epilepsy. (S5)
Phenoxymercaptoenillicin, when intended for the prophylaxis of rheumatic fever. (S4)
Phentolamine.
Phenytoin.
Physostigmine; ophthalmic preparations thereof, when intended for glaucoma. (S4)
Pilocarpine; ophthalmic preparations thereof intended for glaucoma. (S4)
Pindolol.
Pioglitazone.
Piracetam.
Pirbuterol, when contained in respirator solutions. (S2)
Piretanide.
Piroxicam, except when intended for the emergency treatment of acute gout attacks and when intended for the treatment of post-traumatic conditions such as pain, swelling and inflammation, for a maximum period of 5 days. (S2)
Pirprofen.
Potassium canrenoate.
Practolol.
Prazosin.
Primidone.
Probenecid.
Probucol.
Procaterol, when contained in respirator solutions. (S2)
Proctofene.
Propacetamol.
Propiverine.
Propranolol.
Proquazone.
Proscillaridine.
Prothionamide, when intended for oral use.
*Pygeum africanum* (lipido-sterolic complex extract thereof).
Pyrazinamide, when intended for oral use.
Pyrimethamine
Pyrithioxin.
Quinapril.
Racecadotril.
Raloxifene.
Rampiril.
Ranitidine, except where administered orally for short-term symptomatic relief of heartburn and hyperacidity, where the maximum dose is 75 milligrams, the
maximum daily dose is 300 milligrams and the maximum treatment period is two weeks. (S2)

Raubasine.
Rauwolfia alkaloids.
Repaglinide.
Reproterol, when contained in respirator solutions. (S2)
Reserpine (natural or synthetic).
Rimiterol, when contained in respirator solutions. (S2, S4)
Risedronate.
Rofecoxib.
Rosiglitazone.
Roxarzone (3-nitro-4-hydroxyphenylarsonic acid), when intended for veterinary use.
Salbutamol, when contained in respirator solutions. (S2, S4)
Salmetamol, when contained in respirator solutions. (S2, S4)
Solcoseryl; ophthalmic preparations thereof. (S0, S4)
Sotalol.
Spirapril.
Spironolactone.
Strophanthus; its glycosides and their hydrolysis products, and their derivatives, unless listed in another Schedule.
Sulindac.
Suloctidil.
Sulphinpyrazone.
Sulthiame.
Suprofen.
Sylmarin.
Tasosartan.
Tazarotene.
Telmisartan.
Tenidap.
Tenoxicam.
Terazosin.
Terbutaline, when contained in respirator solutions. (S2)
Tenidone.
Terodiline.
Thiacetazone.
Thyroid gland and its active principles and derivatives, unless listed in another Schedule.
Tiagabine.
Tiaprofenic acid, except when intended for the treatment of post-traumatic conditions such as pain, swelling and inflammation, for a maximum period of 5 days. (S2)
Ticlopidine.
Timolol.
Tolamolol.
Tolazamide.
Tolbutamide.
Tolbutamide.
Tolbutamide.
Tolcifenamic acid.
Tolmetin, except when intended for application to the skin. (S1)
Tolterodine.
Topiramate.
Torasemide.
Trandolapril.
Tretinoin.
Triamterene.
Tricaine.
Trimethadione.
Tropicamide.
Tulobuterol, when contained in respirator solutions. (S2)
Ursodeoxycholic acid.
Valdecoxib.
Valproic acid and its derivatives, unless listed in another Schedule.
Valsartan.
Vedaprofen.
Verapamil (iproneratril).
Veratrum alkaloids.
Vigabatrin.
Vincamine.
Vinpocetine.
Vitamin A; preparations thereof for injection and oral preparations and mixtures thereof containing more than 10 000 I.U. per recommended daily dose, except when registered in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947.

Vitamin D; preparations thereof for injection and oral preparations and mixtures thereof containing more than 500 I.U. per recommended daily dose, except when registered in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947.

Xamoterol.

Xipamide.

Zafirlukast.

Zinc salts for oral ingestion where the daily dose is more than 50 milligrams of elemental zinc (SI), except when registered in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947 (Act No. 36 of 1947).

Zomepirac.

- END SCHEDULE 3 -
Schedule 4

(a) All substances referred to in this Schedule are excluded when specifically packed, labelled and used for -
   (i) industrial purposes including the manufacture or compounding of consumer items or products, which have no pharmacological action or medicinal purpose; and
   (ii) analytical laboratory purposes.

(b) All substances referred to in this Schedule include the following:
   (i) The salts and esters of such substances, where the existence of such salts and esters is possible; and
   (iii) all preparations and mixtures of such substances where such preparations and mixtures are not expressly excluded.

(c) In terms of Section 22A(5)(f) of the Act, a practitioner, nurse or a person registered under the Health Professions Act, 1974, other than a medical practitioner or dentist, may prescribe and supply to patients under their care, the Schedule 4 substances and medicines provided for in the Annexures, only within their scope of practice and subject to the conditions determined by the Medicines Control Council. The conditions and the Annexures will be published in the Gazette.

Abacavir.
Acarbose.
Acetarsone diethylamine salt, when intended for injection.
Acyclovir, except when intended for application to the lips in the early treatment of recurrent Herpes simplex virus infections. (S1)
Adenosine.
Adrenaline, when intended for injection. (S2, S3)
Albendazole, except when intended and registered as an anthelmintic in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947.
Alcuronium.
Aldesleukin.
Alfuzosin.
Alisapride.
Amitrine.
Alosetron.
Alphacalcidol, except when registered in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947.
Alphachymotrypsin, when intended for ophthalmic use.
Alprostadil.
Amantadine.
Amifostine.
Aminoglutethimide.
Aminopyrine (amidopyrine).
Amiodarone.
Amiphenazole.
Amprenavir.
Amrinone.
Amsacrine.
Anagrelide.
Anastrozole.
Anticoagulants, except preparations intended for application to the skin. (S1)
Antihemophilic factor.
Antimalarials, excluding chloroquine in combination with proguanil when intended specifically for malaria prophylaxis. (S1)
Antimicrobial substances synthesised in nature or the laboratory, being substances used in the specific treatment of infections, except the following when intended for topical application to the epidermis, nares and external ear:

- Bacitracin; (S1)
- Gramicidin; (S1)
- Griseofulvin; (S2)
- Mupirocin; (S2)
- Natamycin; (S2)
- Nystatin; (S1, S2)
polymyxin B; (S1)

tyrothricin; (S1)

and except when intended for use as germicides and antiseptics, and except

nystatin oral drops (S1) and except nystatin when intended for human vaginal use,
specifically for the treatment of recurrent vaginal candidiasis (S1), and except

phenoxyemethylpenicillin when intended for the prophylaxis of rheumatic fever (S3)
and except when intended for use as indicated below and registered in terms of the
provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock
Remedies Act, 1947:

Ampicillin, cloxacillin, dihydrostreptomycin, penethamate hydriodide and

procaine benzylpenicillin, intra-mammary preparations thereof, containing

tracer dye(s) and intended for the treatment of mastitis in cattle;

amprolium, decoquinate, dinitolmide, ethopabate, lasalocid, maduramicin,

monensin and narasin when intended as anti-coccidial preparations;

avilomycin, avoparcin, carbadox, flavophospholipol, monensin, nitrovin,

olaquindox, virginiamycin and zinc bacitracin when intended to promote
growth as a feed additive;

carnidazole, when intended for trichomonas in pigeons;

chlortetracycline, rolitetracycline and tetracycline; injections thereof, intended

for the treatment of anaplasmosis, footrot, heartwater, navel ill and

pneumonia in sheep and cattle;

chlortetracycline; capsules thereof, for use in pigeons;

chlortetracycline and tetracycline derivatives when intended for topical use in

the management of wounds in animals;

dimetridazole, when intended for trichomonas in pigeons, as an anti-bacterial

preparation for pigs and to promote growth;

doxycycline and oxytetracycline; preparations thereof, except preparations

intended to be used as an additive to feed;

furaltadone, when intended as a single oral dosage for gastro-intestinal

infections;

hygromycin, when intended as an anthelmintic for pigs;

salinomycin, when intended as an anti-coccidial preparation and to promote
growth;
tylosin, when intended for addition to drinking water and feedstuff for administration to poultry and pigs.

Antisera, when intended for veterinary use, except antisera registered in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947.

Apomorphine, when indicated for the treatment of erectile dysfunction. (S2)

Apraclonidine.

Aprotinin.

Arabinosylcytosine.

Arprinocid, except when intended and registered as an anticoccidial preparation in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947.

Arsenamide, when intended for injection.

Artemether and its derivatives.

Artemotil.

L-asparaginase.

Astemizole.

Atipamezole.

Atorvastatin.

Atosiban.

Atovaquone.

Atracurium besilate.

Auranofin.

Azathioprine.

Baclofen.

Basiliximab.

Bee venom, except preparations intended for application to the skin.

Bemegride.

Bethanechol.

Bimatoprost.

Biologicals, injectable preparations thereof, when intended for human use, except tuberculin when intended for human use and except vaccines when intended for human use, and except polyvalent snake antivenom. (S2)

Biperiden.
Bleomycin.
Bretylium tosylate.
Bromocriptine.
Bufenoide.
Bumadizone.
Buserelin.
Busulphan.
Cabergoline.
Calcitonin.
Calcitriol.
Calcium polystyrene sulphonate, when intended for therapeutic purposes.
Cambendazole.
Capecitabine.
Carbachol, except ophthalmic preparations thereof, when intended for glaucoma. (S3)
Carbidopa.
Carboplatin.
Carbuterol, when intended for injection. (S2, S3)
Carmustine.
Cerivastatin.
Ceruletide.
Chlorambucil.
Chlordantoin, when intended for human vaginal use.
Chloroquine, when intended for antirheumatic use. (S1)
Chymopapain, when intended for injection.
Cisapride.
Cisatracurium.
Cisplatin.
Cladribine.
Clanobutin.
Clazuril, except when intended and registered as an anti-coccidial preparation in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947.
Clenbuterol.
Clofazimine.
Clomiphene.
Clomiphene, except when intended and registered as an anthelmintic in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947.
Clotrimazole, except when intended for application to the skin and when intended for human vaginal use, specifically for the treatment of recurrent vaginal candidiasis. (S1)
Colfasceril.
Corticosteroids (natural or synthetic), unless listed in another Schedule, except -
(a) hydrocortisone and hydrocortisone acetate when used as a single active ingredient in a maximum concentration of 1,0 per cent in preparations intended for application to the skin; (S2)
(b) triamcinolone when intended for application to oral lesions; (S2) and
(c) when contained in preparations intended for inhalation. (S2, S3)
Cotetoxazine.
Co-trimoxazole.
Cyclofenil.
Cyclophosphamide and its derivatives, unless listed in another Schedule.
Cyclosporin.
Cyprenorphine.
Cyproterone acetate.
Cytarabine.
Dacarbazine.
Dacliximab.
Daunomycin (actinomycin D).
Dantrolene.
Dapsone and its derivatives, unless listed in another Schedule.
Daunomycin (daunorubicin).
Deferoxamine.
Demecarium.
Desirudin.
Diazoxide.
Dichlorophen, except preparations and mixtures when intended for application to the skin and except when intended for use and registered as an anthelmintic in terms of
the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947.

Diclazuril, except when intended registered as an anti-coccidial preparation in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947.

Dilocodronic acid.

Didanosine.

Diethylcarbamazine.

Dihydralazine.

Dihydrotachysterol.

Di-isopropyl fluorophosphate.

Dilazep.

Diloxanide furoate.

Dimethyl sulfoxide.

Diminazene, except when intended and registered as an antibabesial in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947.

Dinitrophenol.

Dinoprostone.

Diphenemethoxidine.

Diphenidol.

Diprenorphine.

Disodium pamidronate.

Disophenol, except when intended and registered as an anthelmintic in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947.

Disopyramide.

Distigmine.

Ditazole.

Dobutamine.

Docetaxol.

Dolasetron.

Dopa.

Dopamine.
Doxapram.
Doxepin, when intended for application to the skin. (S5)
Doxorubicin.
Drotecognin.
Econazole, except when intended for application to the skin and when intended for human vaginal use, specifically for the treatment of recurrent vaginal candidiasis.
(S1)
Eniliconazole, except when intended for application to the skin. (S1)
Edoxudine.
Edrophonium.
Efavirenz.
Eletiptan.
Emetine, except substances, preparations and mixtures containing less than 0.2 percent of alkaloids, calculated as emetine.
Encainide.
Enoxacin.
Enrofloxacin.
Entacapone.
Epirubicin. (4-epidoxorubicin)
Ergot alkaloids (natural or synthetic); except preparations and mixtures thereof when intended for the treatment of migraine. (S2)
Esomeprazole.
Estramustine.
Etidronate.
Etiproston.
Ethoglucid.
Etofamide.
Etoposide.
Famciclovir.
Famotidine, except when intended for the short term symptomatic relief of heartburn caused by excess acid, where the maximum dose is 10 milligrams, the maximum daily dose (per 24 hours) is 20 milligrams and the maximum treatment period is 2 weeks. (S2)
Fazadinium.
Febantel, except when intended and registered as an anthelmintic in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947.

Fenchlorphos.

Fenoterol, when intended for the prevention or delay of labour and preparations thereof for injection. (S2, S3)

Fenticonazole.

Fertirelin.

Filgrastim.

Finasteride.

Flecainide.

Flosequinan.

Fluconazole.

Flucytosine.

Fludarabine.

Flugestone.

Flunisolide.

Fluorides; except oral medicinal preparations and mixtures thereof containing 0.25 milligrams or more of fluorine as fluoride per recommended daily dose, unless listed in another Schedule. (S1)

5-fluorouracil.

Flurbiprofen, when intended for ophthalmic use. (S1, S2, S3)

Flutamide.

Fluvastatin.

Fondaparinux.

Fotemustine.

Florafur.

Furazolidone.

Galantamine.

Gallamine.

Ganciclovir.

Ganirelix.

Gemcitabine.

Gemtuzumab.
Gestrinone.
Glatiramer.

Glycosaminoglycan polysulphate (previously mucopolysaccharide poly-sulphuric acid ester), except when intended for application to the skin. (S1)

Goserelin.
Granisetron.

Halofantrine.
Halofenate.
Halofuginone, except when intended and registered as an anti-coccidial preparation in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947.

Halogenated hydroxyquinolines, except when intended for application to the skin (S2), and except di-iodohydroxyquinoline when intended and registered as an anti-coccidial preparation in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947 (Act No. 36 of 1947).

Hemin.
Heptaminol.
Hexoprenaline, when intended for the prevention or delay of labour and preparations thereof for injection. (S2, S3)

Hormones (natural or synthetic, including recombinant forms), with either hormonal or anti-hormonal action, unless listed in another Schedule, except-

(a) when specifically intended for emergency postcoital contraception (S2);
(b) when intended for oral contraception (S2, S3);
(c) insulin (S3);
(d) adrenaline (epinephrine) (S2, S3, S4);
(e) corticotrophin (adrenocorticotrophichormone; ACTH) (S5);
(f) Human growth hormone (human somatotropin) -all forms (S5);
(g) zeranol, natural estrogen, and progesterone, when intended and registered as a veterinary production improver in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947;
(h) BST (Bovine somatotropin), when intended and registered as a stock remedy in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947.
Hyaluronidase.
Hyaluronic acid and its derivatives.
Hycanthone.
Hydroxyurea.
Hylan.
Ibandronic Acid.
Ibutilide.
Idarubicin.
Idoxuridine, except when intended for application to the skin. (S1)
Iloprost.
Imatinib.
Imidocarb, except when intended and registered as an antibabesial for the treatment of babesiosis in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947.
Imiglucerase.
Imiquimod.
Indinavir.
Infliximab.
Inosiplex (inosine pranobex).
Interferon alpha.
Interferon beta.
Interferon gamma.
Intra-uterine devices.
Intirifiban.
Irinotecan.
Isepamicin.
Isoconazole, except when intended for application to the skin and when intended for human vaginal use, specifically for the treatment of recurrent vaginal candidiasis.
(S1)
Isopirin.
Isoprenaline (isoproterenol), when intended for injection. (S2, S3)
Isoxsuprime.
Itraconazole.
Ketoconazole, except preparations and mixtures containing not more than 1.0 per cent
of ketoconazole, when intended for the prevention and treatment of dandruff and
except when intended for application to the skin. (S0, S1)

Ketorolac trometamol, except when intended for ophthalmic use. (S3)

Lamivudine.

Lansoprazole, except when intended for the temporary short-term relief of heartburn and
hyperacidity, subject to –
   a) a maximum daily dose of 15mg
   b) a maximum treatment period of 14 days. (S2).

Latanoprost.

Leflunomide.

Letrozole.

Lefallorphan.

Levamisole, except when intended and registered as an anthelmintic and an
immunomodulator in terms of the provisions of the Fertilizers, Farm Feeds,
Agricultural Remedies and Stock Remedies Act, 1947.

Levodopivacaine.

Liarozole.

Local anaesthetics, when intended for ophthalmic and parenteral use, except
oxybuprocaine, proxymetacaine and tetracaine, when contained in eye drops
intended for emergency treatment of acute eye, and except lignocaine when
contained in antimicrobial preparations for injection as well as in ophthalmic
preparations registered in terms of the provisions of the Fertilizers, Farm Feeds,
Agricultural Remedies and Stock Remedies Act, 1947.

Lomustine.

Lopinavir.

Lovastatin.

Lumefantrine.

Lysozyme, except preparations and mixtures when intended for application to the skin.
(S1)

Mecamylamine.

Mefloquine.

Melarsoprol, when intended for injection.

Melphalan and its derivatives, unless listed in another Schedule.
Mephentermine.
Mepirizole.
2-mercaptopropionyl glycine.
6-mercaptopyrurate and its derivatives, unless listed in another Schedule.
Mercury; preparations and mixtures that contain mercury metal and that are intended for medicinal use.
Mesna, when intended for injection. (S2)
Metaproterenol (orciprenaline), when intended for the prevention or delay of labour, and preparations thereof for injection. (S2, S3)
Metergoline.
Methacholine.
Methamprynone.
Methotrexate.
Methoxsalen.
Methysergide.
Metoclopramide.
Metomidate.
Metronidazole.
Mexiletine.
Miconazole, except when intended for application to the skin and except when intended for human vaginal use, specifically for the treatment of recurrent vaginal candidiasis (S1), and except when intended for human use in preparations containing 2 per cent or less of miconazole, when intended for the topical treatment of fungal infections of the mouth (oral candidiasis) (S2).
Mifepristone.
Miglitol.
Milrinone.
Miltefosine.
Minoxidil, except when intended for application to the scalp. (S2)
Misoprostol.
Mitomycin C.
Mitoxantrone.
Mivacurium.
Mizolastine.
Mofebutazone.
Molgramostim.
Mometasone.
Moracizine.
Morazole.
Morphazinamide.
Morphethylbutyne.
Mucogluconan.
Muromonab.
Mycophenolic acid.
Nalidixic acid.
Nalorphine.
Naloxone.
Naltrexone.
Naratriptan.
Netopam.
Nelfinavir.
Neostigmine.
Netobimin.
Nevirapine.
Nicarbazin, except when intended and registered as an anti-coccidial preparation in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947.
Nifuratel.
Nikethamide.
Nilutamide.
Nimorazole.
Nimustine.
Niridazole.
Nitrofurantoin, except preparations thereof intended for application to the skin. (S1)
Nitrofurazone, except preparations thereof intended for application to the skin. (S1)
Nitrous oxide gas, alone or in combination with other gasses.
Nitroxoline.
Nitroxynil, except when intended and registered as an anthelmintic in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947.

Nizatidine, except when intended for oral administration for short-term symptomatic relief of heartburn and hyperacidity, where the maximum dose is 150 milligrams, the maximum daily dose is 300 milligrams and the maximum treatment period is two weeks. (S2)

Obidoxime.
Octreotide.
Omeprazole.
Ondansetron.
Oprelvekin.
Omidazole, except when intended for application to the skin. (S1)
Oseltamivir.
Oxamniquine.
Oxfendazole, except when intended and registered as an anthelmintic in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947.

Oxolinic acid.
Oxybuprocaine, except when contained in eye drops intended for emergency treatment of arc eyes. (S2)
Oxyclozanide, except when intended and registered as an anthelmintic in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947.

Paclitaxel.
Palivizumab.
Paltitrexid.
Pamidronic acid.
Pancuronium.
Pantoprazole.
Paricalcitol.
Penciclovir, except when intended for application to the lips in the early treatment of recurrent Herpes simplex virus infections. (S1)

Penicillamine.
Pentamidine isethionate.
Pentostatin.
Pergolide.
Perhexiline.
Phenacetin, except preparations and mixtures intended for external use and containing not more than 0.1 percent phenacetin as stabilizer.
Phenamidine, except when intended and registered as an antibabesial in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947.
Phenopyrazone.
Phenoxybenzamine.
Phenylbutazone and its derivatives, unless listed in another Schedule.
Physostigmine, except ophthalmic preparations thereof when intended for glaucoma. (S3)
Picrotoxin.
Pilocarpine, except ophthalmic preparations thereof intended for glaucoma. (S3)
Pimecrolimus
Pipemidic acid.
Pirenzepine.
Piribedil.
Piromidic acid.
Podophyllum resin; preparations and mixtures containing more than 20 per cent of podophyllum resin. (S1)
Polyglycerylene-dextran.
Poractant alpha.
Potassium dichromate, except preparations and mixtures containing not more than 15 micrograms of potassium dichromate per dosage unit.
Pralidoxime.
Pramipexole.
Pravastatin.
Praziquantel, except when intended and registered as an anthelmintic in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947.
Procainamide.
Procarbazine.
Propafenone.
Propentofylline, except when intended for veterinary use. (S1)
Propylhexedrine, except when used as a vasoconstrictor and decongestant in nose preparations and inhalants. (S1)
Proteolytic (fibrinolytic) enzymes, when intended for injection. (S1)
Proxymetacaine, except when contained in eye drops intended for emergency treatment of arc eyes. (S2)
Pyridinolcarbamate.
Pyridostigmine.
Quinoronicum sulphate, except when intended and registered as an antibabesial in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947.
Rabeprazole.
Ractopamine, when used as a veterinary production improver.
Radio-active compounds, when used for diagnostic purposes.
Rafoxanide, except when intended and registered as an anthelmintic in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947.
Rapacuronium.
Rasburicase
Recombinant human tissue-type plasminogen activator (rt-PA).
Resorantel, except when intended and registered as an anthelmintic in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947.
Riluzole.
Rimiterol, when intended for injection. (S2, S3)
Ritodrine.
Ritronavir.
Rituximab.
Rizatriptan.
Rocuronium bromide.
Ropinirole.
Rosoxacin.
Rosuvastatin.
Roxatidine.
Salbutamol, when intended for injection. (S2, S3)
Salmefamol, when intended for injection. (S2, S3)
Saquinavir.
Selegiline.
Selenium salts, preparations thereof for injection, when intended for veterinary use.
Sermorelin.
Sertaconazole, except when intended for application to the skin (S1)
Sertindole.
Sildenafil.
Simvastatin.
Sirolimus.
Sodium aurothiomalate.
Sodium cromoglycate, when intended for veterinary use. (S2)
Sodium dihydroazapentacene polysulphonate.
Sodium fluoride; except oral medicinal preparations and mixtures thereof containing 40 milligrams or more per daily dose. (S1)
Sodium nitroprusside.
Solcoseryl, except preparations intended for application to the skin, to the mucous membranes of the mouth and to the lips and except ophthalmic preparations thereof. (S0, S3).
Stavudine.
Strapto kinase
Strychnine, subject thereto that for the control of problem predatory mammals -

(a) it shall only be supplied on a written prescription issued by a State Veterinarian, for use in the particular State Veterinarians' area of jurisdiction, in a quantity not exceeding 5 grams; and

(b) the State Veterinarian shall obtain prior written approval for such use from the Director of the concerned provincial conservation institution or authority in his area of jurisdiction, a copy of which shall be attached to the written prescription; and except preparations and mixtures containing 0,2 per cent or less of strychnine when included in Schedule 2.

Styramate.
Sulphonamides, except -

(a) substances, preparations and mixtures intended for application to the eyes, nares and vagina; (S2)

(b) silver sulphadiazine, when intended for application to the skin in the short term treatment of minor burns, provided that the pack size is limited to a maximum of 50 grams; (S2)

(c) when registered in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947.

Sumatriptan.
Suramin.
Suxamethonium.
Suxethonium.
Tacrine.
Tacrolimus.
Tadalafil.
Tamoxifen.
Tamsulosin.
Tasonermin.
Tegafur.
Tegaserod.
Temozolomide.
Tenecteplase.
Teniposide.
Terbinafine, except when intended for application to the skin. (S1)
Terconazole.
Terfenadine.
Teriparatide.
Tetramisole, except when intended and registered as an anthelmintic in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947.
Theophylline and its derivatives, unless listed in another Schedule; preparations intended for injection. (S2)
Thiabendazole, except when intended for application to the skin (S1) and except when intended and registered as an anthelmintic in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947.

Thioguanine.

Thymopentin.

Tibolone.

Tiludronic Acid.

Tin fluoride, when intended for injection

Tinidazole.

Tioconazole, except when intended for application to the skin and when intended for human vaginal use, specifically for the treatment of recurrent vaginal candidiasis. (S1)

Tirilazad.

Tocainide.

Tolcapone.

Tolrestat.

Toltrazuril, except when intended and registered as an anti-coccidial preparation in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947.

Topotecan.

Toremifene.

Tranexamic acid.

Trastuzumab.

Travoprost.

Treosulfan.

Triclabendazole, except when intended and registered as an anthelmintic in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947.

Triethylene thiophosphoramide.

Trifluorothymidine.

Trimetaphane.

Trimethoprim, except when specifically intended and registered for the treatment of gastro-enteritis and pneumonia in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947.
Trimetrexate.
Trioxsalen.
Triptorelin.
Tromantadine.
Trometamol.
Tropisetron.
Tuberculin, when intended for veterinary use. (S2)
Tubocurarine.
Unoprostone.
Urapidil.
Urethane.
Urokinase.
Vaccines for veterinary use except vaccines registered in terms of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947.
Valaciclovir.
Vanillic acid diethylamide.
Vardenafil.
Vasoactive intestinal polypeptide.
Vecuronium bromide.
Verteporfin.
Vidarabine.
Vinblastin.
Vincristin.
Vindesine.
Vinorelbine.
Voriconazole.
Vorozole.
Zalcitabine.
Zanamivir.
Zidovudine (AZT).
Zolmitriptan.
Zoledronic acid.

- END SCHEDULE 4 -
Schedule 5 and specified Schedule 5

(a) All substances referred to in this Schedule include the following:
   (i) The salts and esters of such substances, where the existence of such salts and esters is possible; and
   (ii) All preparations and mixtures of such substances where such preparations and mixtures are not expressly excluded.

(b) In terms of Section 22A(5)(f) of the Act, a practitioner, nurse or a person registered under the Health Professions Act, 1974, other than a medical practitioner or dentist, may prescribe and supply to patients under their care, the Schedule 5 substances and medicines provided for in the Annexures, only within their scope of practice and subject to the conditions determined by the Medicines Control Council. The conditions and the Annexures will be published in the Government Gazette.

(c) Specified Schedule 5 substances listed in this schedule are subject to additional control in terms of section 22A of the Act as required under the provisions of the 1971 Convention on Psychotropic Substances and are denoted by "***".

Acitretin.
Amisulpride.
Amitryptyline and its derivatives, unless listed in another Schedule.
Amoxapine.
Anaesthetic preparations containing pregnanedione derivatives.
Androstanolone.
Androstenediol.
Aponal.
Apronalide.
Azacyclonol.

Barbituric acid** and its derivatives**, unless listed in another Schedule, excluding-
(a) amobarbital, cyclobarbital, pentobarbital and secobarbital (S6), and
(b) preparations and mixtures containing not more than 90 milligrams of
phenobarbital** per minimum recommended or prescribed dose when intended
for continued use in epilepsy. (S3)

Benactyzine and its derivatives, unless listed in another Schedule.

Benfluuramate.

Benzocamine.

Benzodiazepines** and their derivatives**, unless listed in another Schedule and except
flunitrazepam. (S6)

Benzquinamide.

Beta-aminopropylbenzene and beta-aminoisopropylbenzene, any compound structurally
derived from either of these substances by substitution in the side chain or by ring
closure therein (or by both such substitution and such ring closure) and any salt or
substance falling under the above, except preparations and mixtures of the above
when used as vasoconstrictors and decongestants in antihistamine nose and eye
preparations and except when contained in appliances for inhalation in which the
substance is absorbed in solid material and excluding cathine ((+)-
norpseudoephedrine), ephedrine, etafedrine, N-methylephedrine, N-
diethylaminoethylephedrine, phenylpropanolamine, prenylamine and preparations
and mixtures thereof except substances listed in Schedule 7. (S1, S2, S7)

Bolandiol.

Bolasterone.

Boldenone.

Bromides; preparations and mixtures thereof containing 80 milligrams or more of
bromine as bromide per recommended daily dose, except when specifically
packaged, labelled and used for industrial purposes including the manufacture or
compounding of consumer items or products which have no pharmacological action
or medicinal purpose, which are intended to be ingested by man or animals as food
or applied to the body as a cosmetic and which are approved for such use in terms
of the Foodstuffs, Cosmetic and Disinfectants Act, 1972 and for analytical laboratory
purposes. (S2)

Bromisovalum.
Brotizolam**.
Bupropion.
Buspirone.
Etriptyline.
Butyrophenones.
Carbromal.
Chloral derivatives, unless listed in another Schedule.
Chloromezanone, except mixtures thereof where the maximum recommended or
prescribed dose does not exceed 100 milligrams of chloromezanone. (S2)
Chlorprothixene.
Citalopram.
Clomacran.
Clomethiazole (previously listed as "heminevrin").
Clomipramine.
Clopenthixol.
Clostebol.
Clothiapine.
Clozapine.
Corticotrophin (adrenocorticotropic hormone; ACTH).
Cyclobenzaprine.
Danazol.
Deanol and its derivatives, unless listed in another Schedule, except when specifically
packaged, labelled and used for industrial purposes including the manufacture or
compounding of consumer items or products which have no pharmacological action
or medicinal purpose, which are intended to be ingested by man or animals as food
or applied to the body as a cosmetic and which are approved for such use in terms
of the Foodstuffs, Cosmetic and Disinfectants Act, 1972, and for analytical
laboratory purposes. (S1)
Dehydrochloromethyltestosterone
Desflurane.
Detomidine
Dexfenfluramine.
Dexmedetomidine.
Dextropropoxypophene; preparations and mixtures for oral use containing not more than 135 milligrams of dextropropoxypophene, calculated as the base, per dosage unit or with a concentration of not more than 2.5 percent in undivided preparations. (S6)

Diprenorphine.
Donepezil.
Dothiepin.
Doxepin, except when intended for application to the skin. (S4)
Droperidol.
Drostanolone.
Ecothiopate.
Emylcamate.
Enflurane.

Ephedrine (natural or synthetic), except when contained in products registered in terms of the Act. (S1, S2)

Epiteostanol.
Escitalopram.
Ethchlorvynol**.
Ether (diethyl ether); except substances, preparations and mixtures containing more than 20 per cent of ether. (S1)

Ethinamate** and its derivatives**, unless listed in another Schedule.

Ethylestrenol.
Etodroxizine, except preparations and mixtures thereof when used solely as an antihistamine. (S2)

Etomidate.
Etretinate.
Fencamfamine**.
Fenfluramine.
Flumazenil.
Fluoxetine.
Fluoxymesterone.
Flupenthixol.
Fluspiriene.
Fluvooxamine.
Formebolone.
Furazabol.
Haloperidol.
Halothane.

Hedonal and its esters, except when specifically packaged, labelled and used for industrial purposes including the manufacture or compounding of consumer items or products which have no pharmacological action or medicinal purpose, which are intended to be ingested by man or animals as food or applied to the body as a cosmetic and which are approved for such use in terms of the Foodstuffs, Cosmetic and Disinfectants Act, 1972, and for analytical laboratory purposes.

Human growth hormone (human somatotropin) - all forms.
Hydroxyzine.
Imipramine and its derivatives, unless listed in another Schedule.
Iproniazid.
Isoflurane.
Isotretinoin.
Ketamine.

Lithium salts, when intended for medicinal use, except when intended for application to the skin. (S2)
Lofepramine.
Loxapine.
Maprotiline.
Mazindol**.
Mebolazine

Mechlorethamine and its derivatives, unless listed in another Schedule.
Meclofenoxate.
Medetomidine.
Melitracene.
Mephenoxalene.
Mepropramide**.
Mesterolone
Metandienone
Metenolone.
Methandriol.
Methoxyflurane.
Methyltestosterone.
Metrifonate.
Mianserin.
Mibolerone.
Milnacipran.
Mirtazapine.
Moclobemide.
Molindone.
Nalbuphine.
Nandrolone.
Nefazodone.
Nomifensine.
Norclostebol.
Norethandronlone.
Olanzapine.
Oxabolone.
Oxandrolone.
Oxymesterone.
Oxymetholone.
Oxypertine.
Paraldehyde.
Pargyline.
Paroxetine.
Pemoline** and its complexes**.
Phenethylhydrazine.
Phenothiazine and its derivatives, unless listed in another Schedule, except preparations and mixtures containing promethazine or dimethothiazine or their salts when used solely as an antihistaminic (S2), and except preparations containing promethazine or its salts when intended specifically for the treatment of travel sickness or application to the skin, (S2), and except phenothiazine when intended and registered as an anthelmintic in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947.
Phentermine**.
Pimethixene, except preparations and mixtures thereof when used solely as an antihistaminic. (S2)
Pimozide.
Pipradrol**.
Pizotifen, except preparations and mixtures thereof when used solely as an antihistaminic or when intended for the prophylaxis of migraine. (S2)
Prasterone (Dehydroepiandrosterone, DHEA).Prolintane.
Propofol.
Quetiapine.
Quinbolone.
Quinupramine.
Reboxetine.
Risperidone.
Rivastigmine.
Romifidine.
Sertraline.
Sevoflurane.
Sibutramine.
Stanozolol.
Stenbolone.
Sulphonmethane.
Sulpyride.
Testolactone.
Testosterone, except subcutaneous implants thereof when specifically intended and registered as a veterinary production improver in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947.
Thioguanosine.
Thiothixene.
Tiapride.
Tiletamine.
Tizanidine.
Tramadol.
Tranylcypromine.
Trazodone.
Trenbolone, except subcutaneous implants thereof when specifically intended and registered as a veterinary production improver in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947.

Trihexyphenidyl.

L-tryptophan, when intended for medicinal use, except when intended for medicinal use as supplementation for nutritional purposes. (S1)

Venlafaxine.

Viloxazine.

Xylazine.

Zaleplon.

Zimelidine.

Ziprasidone.

Zolazepam.

Zolpidem**.

Zopiclone.

Zotepine.

Zuclopenthixol.

- END SCHEDULE 5 -
Schedule 6

(a) All substances referred to in this Schedule include the following (unless expressly excluded or unless listed in another Schedule):

(i) the isomers of such substances, where the existence of such isomers is possible within the chemical designation;

(ii) the esters and ethers of such substances and of the isomers referred to in (i), as well as the isomers of such esters and ethers, where the existence of such esters, ethers and isomers is possible;

(iii) the salts of such substances and of the isomers referred to in (i), as well as the salts of the esters, ethers and isomers referred to in (ii), where the existence of such salts is possible;

(iv) the isomers of any of the salts referred to in (iii), where the existence of such isomers is possible;

(v) all preparations and mixtures of any of the above.

(b) In terms of Section 22A(5)(f) of the Act, a practitioner, nurse or a person registered under the Health Professions Act, 1974, other than a medical practitioner or dentist, may prescribe and supply to patients under their care, the Schedule 6 substances and medicines provided for in the Annexures, only within their scope of practice and subject to the conditions determined by the Medicines Control Council. The conditions and the Annexures will be published in the Gazette.

Acetorphine.

Acetyldihydrocodeine, except preparations and mixtures when compounded with one or more therapeutically active substances and containing 20 milligrams or less of acetyldihydrocodeine (calculated as base) per dosage unit and liquid oral preparations and mixtures containing 20 milligrams or less of acetyldihydrocodeine (calculated as base) per 5 millilitre dosage unit. (S2)
Acetylmethadol.
Alfentanil.
Allylprodine.
Alphacetylmethadol.
Alphameprodine.
Alphamethadol.
Alphaprodine.
Amobarbital.
Anileridine.
Benzethidine.
Benzphetamine.
Benzylmorphine.
Betacetylmethadol.
Betameprodine.
Betamethadol.
Betaprodine.
Bezitramide.
Buprenorphine.
Butalbital.
Butorphanol
Cathine ((+)-norpseudoephedrine), except preparations and mixtures containing 50 milligrams or less of cathine per dosage unit. (S2)
Chlorodyne (Chloroform and Morphine Tincture BP 1980) or any preparation or mixture thereof described as chlorodyne; except preparations and mixtures containing 5.0 percent or less of chlorodyne in combination with other active medicinal substances. (S2)
Chlorphentermine.
Clonitazene.
Coca leaf and any salt, compound, derivative or preparation of coca leaf and any salt, compound, derivative or preparation thereof that is chemically equivalent or identical to any of these substances, whether obtained directly or indirectly by extraction from material or substances obtained from plants, or obtained independently by chemical synthesis, or by a combination of extraction and chemical synthesis, except
decocainized coca leaf and extractions of coca leaf where such extractions contain no cocaine or ecgonine.

Codeine (methylmorphine); except preparations and mixtures when compounded with one or more therapeutically active substances and containing 20 milligrams or less of codeine (calculated as base) per dosage unit and liquid oral preparations and mixtures containing 20 milligrams or less of codeine (calculated as base) per 5 milliliter dosage unit. (S2)

Codoxime.

Cyclobarbital.

Desomorphine.

Dextromoramide.

Dextropropoxyphene, except preparations and mixtures for oral use containing 135 milligrams or less of dextropropoxyphene, calculated as the base, per dosage unit or with a concentration of not more than 2.5 percent in undivided preparations. (S5)

Diampromide.

Diethylpropion (amfepramone).

Diethylthiambutene.

Difenoxin (or diphenoxylate acid), except mixtures containing, per dosage unit, 0.5 milligrams or less of difenoxin, calculated as the base, and a quantity of atropine sulphate equal to at least 5.0 per cent of such quantity of difenoxin, calculated as the base, as is present in the mixture. (S2)

Dihydrocodeine, except preparations and mixtures when compounded with one or more therapeutically active substances and containing 20 milligrams or less of dihydrocodeine (calculated as base) per dosage unit and except liquid oral preparations and mixtures containing 20 milligrams or less of dihydrocodeine (calculated as base) per 5 milliliter dosage unit. (S2)

Dihydroetorphine.

Dihydromorphone.

Dimenoxadol.

Dimepheptanol.

Dimethylthiambutene.

Dioxaphethyl butyrate.
Diphenoxylate, except preparations containing not more than 2.5 milligrams of
diphenoxylate, calculated as the base, and not less than 25 micrograms of atropine
sulphate per dosage unit. (S1)

Dipipanone.

Dronabinol [(−)-transdelta-9-tetrahydrocannabinol], when intended for therapeutic
purposes. (S7)

Drotebanol.

Ecgonine, and the esters and derivatives thereof that are convertible to ecgonine and
cocaine.

Ethylmethylthiambutene.

Ethylmorphine; except preparations and mixtures when compounded with one or more
therapeutically active substances and containing 20 milligrams or less of
ethylmorphine (calculated as base) per dosage unit and liquid oral preparations and
mixtures containing 20 milligrams or less of ethylmorphine (calculated as base) per 5
millilitre dosage unit. (S2)

Etonitazene.

Etorphine and analogues.

Etoperidine.

Fenproporex.

Fentanyl, when intended for therapeutic purposes. (S7)

Flunirazepam.

Furethidine.

Glutethimide.

Hydrocodone (dihydrocodeinone).

Hydromorpinol (14-hydroxydihydromorphine).

Hydromorphone (dihydromorphinone).

Hydroxypethidine.

Isomethadone.

Ketobemidone.

Levomoramide.

Levorphanol.

Mecloqualone.

Mefenorex.
Meptazinol.
Metazocine.
Methadone.
Methadone-intermediate.
Methorphan, including levomethorphan and racemethorphan, but excluding
dextromethorphan. (S2)
Methyldesorphine.
Methyldihydromorphine.
Methylphenidate and its derivatives, unless listed in another Schedule.
Metopon.
Moramido-intermediate.
Morphendine.
Morphine, except preparations and mixtures of morphine containing 0,2 percent or less
of morphine, calculated as anhydrous morphine. (S2)
Morphine methobromide and other pentavalent nitrogen morphine derivatives.
Morphine-N-oxide and its derivatives.
Myrophine (myristylbenzylmorphine).
Nicocodine.
Nicodicodine.
Nicomorphine.
Noracymethadol.
Norcodeine; except preparations and mixtures when compounded with one or more
therapeutically active substances and containing 20 milligrams or less of norcodeine
(calculated as base) per dosage unit and liquid oral preparations and mixtures
containing 20 milligrams or less of norcodeine (calculated as base) per 5 millilitre
dosage unit. (S2)
Norlevorphanol.
Normethadone.
Normorphine (demethylmorphine or N-demethylated morphine).
Norpipanone.
Opium and opiates and any salt, compound, derivative or preparation of opium or
opiates, whether obtained directly or indirectly by extraction from material or
substances obtained from plants, or obtained independently by chemical synthesis,
or by a combination of extraction and chemical synthesis, except mixtures containing 0.2 per cent or less of morphine, calculated as anhydrous morphine. (S2)

Opium-poppy and poppy straw, whether obtained directly or indirectly by extraction from material or substances obtained from plants, or whether obtained independently by chemical synthesis, or by a combination of extraction and chemical synthesis.

Oxycodone (14-hydroxydihydrocodeinone or dihydrohydroxycodeinone).

Oxymorphone (14-hydroxydihydromorphinone or dihydrohydroxymorphinone).

Pentazocine.

Pentobarbital.

Pethidine, pethidine-intermediate A, pethidine-intermediate B and pethidine-intermediate C (S8)

Phenadoxone.

Phenampromide.

Phenacetin.

Phendimetrazine.

Phenoperidine.

Pholcodeine, except preparations and mixtures when compounded with one or more therapeutically active substances and containing 20 milligrams or less of pholcodeine (calculated as base) per dosage unit and liquid oral preparations and mixtures containing 20 milligrams or less of pholcodeine (calculated as base) per 5 millilitre dosage unit. (S2)

Piminodine.

Piritramide.

Proheptazine.

Properidine.

Propiram.

Racemoramide.

Racemorphan.

Remifentanil.

Secobarbital.

Sufentanil.

Thebacon.

Thebaine.
Tilidine.
{(-)-transdelta-9-tetrahydrocannabinol - see dronabinol}
Trimeperidine.
Zipeprol.

- END SCHEDULE 6 -
Schedule 7

All substances referred to in this Schedule include the following (unless expressly excluded or unless listed in another Schedule):

(a) The isomers of such substances, where the existence of such isomers is possible within the chemical designation;

(b) The esters and ethers of such substances and of the isomers referred to in (a), as well as the isomers of such esters and ethers, where the existence of such esters, ethers and isomers is possible;

(c) The salts of such substances and of the isomers referred to in (a), as well as the salts of the esters, ethers and isomers referred to in (b), where the existence of such salts is possible;

(d) The isomers of any of the salts referred to in (c), where the existence of such isomers is possible;

(e) All preparations and mixtures of any of the above.

(Trivial or unofficial names are marked *)

Aminorex.
Amphetamine. (S8)
Brolamfetamine (±)-4-bromo-2,5-dimethoxy-a-methylphenethylamine *(DOB).
4-bromo-2,5-dimethoxyphenethylamine (2C-B) *(Nexus).
Bufotenine (N,N-dimethylserotonin).
Cannabis (dagga), the whole plant or any portion or product thereof, except:

(a) when separately specified in the Schedules; (S6) or
(b) processed hemp fibre containing 0.1 per cent or less of tetrahydrocannabinol and products manufactured from such fibre, provided that the product does not contain whole cannabis seeds and is in a form not suitable for ingestion, smoking or inhaling purposes; or
(c) processed product made from cannabis seeds containing not more than 10mg/kg (0.001 per cent) of tetrahydrocannabinol and does not contain whole cannabis seeds.

["Processed" means treated by mechanical, chemical or other artificial means but does not include- (a) harvesting; or (b) the natural process of decay]"

Cathinone (\((\pm)\)-(S)-2-aminopropiophenone).

Dexamphetamine. (S8)

Diethyltryptamine \([3-(2-(diethylamino) ethyl) indole]\) *(DET).

\((\pm)\)-2,5-dimethoxy-\(\alpha\)-methylphenethylamine *(DMA).

2,5-dimethoxy-\(\alpha\)-4-dimethylphenethylamine *(DOM, STP) and its derivatives.

3-(1,2-dimethylheptyl)-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-dibenzo[b,d]pyran-1-ol *(DMHP).

\((\pm)\)-N,\(\alpha\)-dimethyl-3, 4-(methylenedioxy)phenethylamine * (MDMA).

Dimethyltryptamine \([3-(2-(dimethylamino) ethyl) indole]\) *(DMT).

\((\pm)\)-4-ethyl-2,5-dimethoxy-\(\alpha\)-phenethylamine *(DOET).

Dronabinol \([(-)\text{-trans}delt-9\text{-tetrahydrocannabinol}] \) (S6)

Etilamfetamine \((\text{N-ethylamphetamine})\)

Etryptamine.

Fenetylline.

Fentanyl-analogues (unless listed in another Schedule) including:

- acetyl-alpha-methylfentanyl;
- alpha-methylfentanyl;
- alpha-methylfentanyl-acetanilide;
- alpha-methylthiofentanyl;
- benzyl-fentanyl;
- beta-hydroxyfentanyl;
- beta-hydroxy-3-methylfentanyl;
- 3-methylfentanyl and its two isomeric forms:
  - cis-N-(3-methyl-1-(2-phenethyl)-4-piperidyl) propionanilide; and
  - trans-N-(3-methyl-1-(2-phenethyl)-4-piperidyl) propionanilide;
- 3-methylthiofentanyl;
- para-fluorofentanyl; and
- thiofentanyl. (S6)

Gamma-hydroxybutyrate (GHB).
Harmaline (3,4-dihydroharmine).
Harmine [7-methoxy-1-methyl-9H-pyrido (3,4-b)-indole].
Heroin (diacetylmorphine).
3-hexyl-7,8,9,10-tetrahydro-6,6,0-trimethyl-6H-dibenzo [b,d]-pyran-1-01* (parahexyl).
Lefetamine *(SPA).
Lysergide (Lysergic acid diethylamide)*(LSD).
Mescaline (3,4,5-trimethoxyphenethylamine).
Mesocarb.
Methamphetamine and methamphetamine racemate.
Methaqualone and any preparation containing methaqualone.
Methcathinone.
2-methoxy-a-methyl-4,5-(methyleneedioxy)phenethylamine *(MMDA).
\( p \)-methoxy-a-methylphenethylamine *(PMA).
4 methyaminorex.
{(Methyleneedioxyamphetamine *(MDA) and its analogues - see tenamfetamine}
Methyprylon.
Nabilone.(S8)
Pethidine-analogues, including:
1-methyl-4-phenyl-4-propionoxy-piperidine *(MPPP);
1-methyl-4 phenyl-1,2,5,6-tetrahydropiperidine *(MPTP); and
1-phenylethyl-4-phenyl-4-acetyloxy-piperidine *(PEPAP).
Phencyclidine *(PCP) and its congeners, including :
eticyclidine (N-ethyl-1-phenylcyclohexylamine *(PCE));
rolycyclidine (1-(1-phenylcyclohexyl) pyrrolidine *(PHP or PCPY)); and
tenocyclidine (1-[1-(2-thienyl) cyclohexyl] piperidine *(TCP).
Phenmetrazine.
Psilocin (4-hydroxy-NN-dimethyltryptamine).
Psilocybine (4-phosphoryoxy-NN-dimethyltryptamine).
Pyrovalerone (4'-methyl-2-(1-pyrrolidinyl) valerophenone).
Tenamfetamine (methyleneedioxyamphetamine *(MDA)) and its analogues:
(\(+\))-N-ethyl-a-methyl-3,4-(methyleneedioxy) phenethylamine *(N-ethyl MDA):
(\(+\))-N-[a-methyl-3,4-(methyleneedioxy) phenethyl] hydroxyamphetamine *(N-hydroxy MDA).
Tetrahydrocannabinol and their alkyl homologues, except:
(a) when separately specified in the Schedules;
(b) dronabinol ((-)-transdelta-9-tetrahydrocannabinol), when intended for therapeutic purposes. (S6);

(c) in hemp seed oil, containing 10mg/kg or less of tetrahydrocannabinols, when labelled "Not to be taken" *(Not for internal human use - alternatively)*; or

(d) in products for purposes other than internal human use containing 10mg/kg or less of tetrahydrocannabinols.

["Hemp seed oil" means the oil obtained by cold expression from the ripened fruits (seeds) of *Cannabis sativa.*]

(±)-3, 4, 5-trimethoxy-α-methylphenethylamine *(TMA).*

- END SCHEDULE 7 -
Schedule 8

All substances referred to in this Schedule include the following (unless expressly excluded or unless listed in another Schedule):

(a) the isomers of such substances, where the existence of such isomers is possible within the chemical designation;

(b) the esters and ethers of such substances and of the isomers referred to in (a), as well as the isomers of such esters and ethers, where the existence of such esters, ethers and isomers is possible;

(c) the salts of such substances and of the isomers referred to in (a), as well as the salts of the esters, ethers and isomers referred to in (b), where the existence of such salts is possible;

(d) the isomers of any of the salts referred to in (c), where the existence of such isomers is possible;

(e) all preparations and mixtures of any of the above.

Amphetamine and its salts; preparations thereof. (S7)
Dexamphetamine and its salts; preparations thereof. (S7)
Nabilone. (S7)

- END SCHEDULE 8 -

These Schedules come into operation on 2 May 2003.

ME TSHABALALA-MSIMANG
MINISTER OF HEALTH